Market cap
$54 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.8
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.6 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.1
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-6.5
-
Face value
--
-
Shares outstanding
7,387,701
8 Years Aggregate
CFO
$-288.42 Mln
EBITDA
$-347.67 Mln
Net Profit
$-331.66 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Kezar Life Sciences (KZR)
| 15.9 | -1.1 | 17.2 | 72.7 | -34.5 | -32.5 | -- |
|
BSE Sensex*
| -8.6 | 2.9 | 1.8 | -5.1 | 6.9 | 8.1 | 11.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Kezar Life Sciences (KZR)
| -6.4 | -29.1 | -86.5 | -57.9 | 220.3 | 30.2 | -83.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Kezar Life Sciences (KZR)
|
7.3 | 53.9 | 0.0 | -45.2 | -- | -61 | -- | 0.8 |
| 278.1 | 37,764.0 | 4,286.9 | 577.2 | 20.3 | 88.2 | 70.9 | 35.1 | |
| 230.8 | 14,299.5 | 867.5 | 506.6 | -0.6 | -- | 25 | 25.4 | |
| 51.9 | 13,354.5 | 2,375.5 | 833.4 | 41.5 | 40.7 | 17.6 | 6.9 | |
| 131.8 | 17,452.8 | 1,080.2 | -433.2 | -39.8 | -- | -- | 55.7 | |
| 167.7 | 29,936.9 | 16,632.0 | 1,385.0 | 14.1 | 22.3 | 22.3 | 4.9 | |
| 460.2 | 13,347.1 | 2,678.3 | 460.4 | 21.3 | 103.2 | 29.4 | 22.3 | |
| 609.9 | 64,176.2 | 14,919.6 | 4,423.4 | 34.9 | 14.2 | 14.9 | 2.0 | |
| 536.6 | 23,174.2 | 3,169.8 | 1,287.4 | 51.3 | 20.6 | 20.2 | 3.9 | |
| 451.6 | 112,924.4 | 12,255.1 | 4,338.3 | 32.0 | 23.7 | 26.4 | 5.8 |
Shareholding Pattern
View DetailsAbout Kezar Life Sciences (KZR)
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product... candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. Read more
-
Co-Founder, CEO & Director
Dr. Christopher J. Kirk Ph.D.
-
Co-Founder, CEO & Director
Dr. Christopher J. Kirk Ph.D.
-
Headquarters
South San Francisco, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Kezar Life Sciences (KZR)
What is the current share price of Kezar Life Sciences Inc (KZR) Today?
The share price of Kezar Life Sciences Inc (KZR) is $7.29 (NASDAQ) as of 11-May-2026 09:30 EDT. Kezar Life Sciences Inc (KZR) has given a return of -34.55% in the last 3 years.
What is the current PB & PE ratio of Kezar Life Sciences Inc (KZR)?
Since, TTM earnings of Kezar Life Sciences Inc (KZR) is negative, P/E ratio is not available.
The P/B ratio of Kezar Life Sciences Inc (KZR) is 0.77 times as on 12-Jun-2026, a 81 discount to its peers’ median range of 4.14 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-0.79
|
0.63
|
|
2024
|
-0.56
|
0.40
|
|
2023
|
-0.07
|
0.04
|
|
2022
|
-0.75
|
0.18
|
|
2021
|
-1.53
|
0.42
|
What is the 52 Week High and Low of Kezar Life Sciences Inc (KZR)?
The 52-week high and low of Kezar Life Sciences Inc (KZR) are Rs 7.55 and Rs 0.13 as of 19-Jun-2026.
What is the market cap of Kezar Life Sciences Inc (KZR)?
Kezar Life Sciences Inc (KZR) has a market capitalisation of $ 54 Mln as on 12-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Kezar Life Sciences Inc (KZR)?
Before investing in Kezar Life Sciences Inc (KZR), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.